Crispr Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Piper Jaffray Companies raised their Q1 2020 earnings per share estimates for shares of Crispr Therapeutics in a research report issued on Tuesday, November 26th, according to Zacks Investment Research. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the company will earn ($1.20) per share for the quarter, up from their prior estimate of ($1.29). Piper Jaffray Companies currently has a “Buy” rating and a $104.00 target price on the stock. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.
Several other analysts have also recently weighed in on CRSP. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Oppenheimer lifted their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group boosted their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $69.54.
CRSP opened at $72.37 on Thursday. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The company has a market capitalization of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The stock has a fifty day moving average of $54.81 and a 200-day moving average of $47.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last quarter. 21.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. lifted its holdings in shares of Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Orbimed Advisors LLC bought a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at approximately $21,167,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: What is a CD ladder?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.